Denali Therapeutics
DNLI
67 hedge funds and large institutions have $949M invested in Denali Therapeutics in 2018 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 29 increasing their positions, 13 reducing their positions, and 8 closing their positions.
123% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 13
113% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 8
16% more funds holding
Funds holding: 58 → 67 (+9)
1.18% more ownership
Funds ownership: 64.69% → 65.87% (+1.2%)
21% less capital invested
Capital invested by funds: $1.2B → $949M (-$252M)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
94% less call options, than puts
Call options by funds: $12K | Put options by funds: $191K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$38.3M |
| 2 |
Fidelity International
Hamilton,
Bermuda
|
+$6.63M |
| 3 |
JRP
Jasper Ridge Partners
Menlo Park,
California
|
+$5.3M |
| 4 |
Millennium Management
New York
|
+$3.24M |
| 5 |
State Street
Boston,
Massachusetts
|
+$3.02M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$28.2M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
-$6.4M |
| 3 |
Norges Bank
Oslo,
Norway
|
-$5.23M |
| 4 |
BM
Bridger Management
New York
|
-$5.05M |
| 5 |
LCM
Laurion Capital Management
New York
|
-$2.33M |
DNLI Hedge Fund Activity: Q2 2018 in Review
67 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Denali Therapeutics (DNLI) for Q2 2018, worth a combined $949M — down 21% from $1.2B a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new DNLI positions and 8 closed out — a net gain of 9 holders — while 29 added to existing stakes and 13 trimmed.
The largest buyer was Vanguard Group, adding an estimated $38.3M. The largest seller was Fidelity Investments, cutting an estimated $28.2M.
- 67 institutional investors held Denali Therapeutics (DNLI) as of Q2 2018, up from 58 in Q1 2018.
- Funds reported $949M of Denali Therapeutics stock for Q2 2018, down 21% quarter-over-quarter.
- 17 funds opened new Denali Therapeutics positions in Q2 2018 and 8 closed out, a net change of +9 holders.
- The largest Denali Therapeutics buyer in Q2 2018 was Vanguard Group, an estimated $38.3M added.
- The largest Denali Therapeutics seller in Q2 2018 was Fidelity Investments, an estimated $28.2M sold.
Based on aggregated 13F filings for Q2 2018.